Company news
Kura Oncology, Inc. news in 2022
Kura Oncology, Inc.'s news releases, calls and decks from 2022, newest first.
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
December 9, 2022
Kura Oncology to Host Investor Event on December 10, 2022
November 30, 2022
Kura Oncology Reports Third Quarter 2022 Financial Results
November 2, 2022
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
November 2, 2022
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
November 2, 2022
Kura Oncology to Report Third Quarter 2022 Financial Results
October 26, 2022
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
October 25, 2022
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
August 31, 2022
Kura Oncology Reports Second Quarter 2022 Financial Results
August 2, 2022
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
August 1, 2022
Kura Oncology to Report Second Quarter 2022 Financial Results
July 26, 2022
Kura Oncology Reports First Quarter 2022 Financial Results
May 3, 2022
Kura Oncology to Report First Quarter 2022 Financial Results
April 26, 2022
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
April 7, 2022
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
March 7, 2022
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
February 16, 2022
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
February 9, 2022
Kura Oncology Expands Leadership Team with Key Promotions
January 31, 2022
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
January 19, 2022
Calls in 2022
Decks in 2022
- ASH 2022
Conference · 18 slides · November 2022